37 related articles for article (PubMed ID: 27636366)
1. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations.
DiStefano MJ; Levy JF; Odouard IC; Anderson GF
Value Health; 2023 Nov; 26(11):1618-1624. PubMed ID: 37689264
[TBL] [Abstract][Full Text] [Related]
2. 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
Büssgen M; Stargardt T
Appl Health Econ Health Policy; 2023 Sep; 21(5):751-759. PubMed ID: 37249741
[TBL] [Abstract][Full Text] [Related]
3. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
4. Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act.
Vogel M; Kakani P; Chandra A; Conti RM
Nat Biotechnol; 2024 Mar; 42(3):406-412. PubMed ID: 38297186
[TBL] [Abstract][Full Text] [Related]
5. The Constitutionality of Medicare Drug-Price Negotiation under the Takings Clause.
Bhargava R; Brown N; Kapczynski A; Kesselheim AS; Lim SY; Morten CJ
J Law Med Ethics; 2023; 51(4):961-971. PubMed ID: 38477274
[TBL] [Abstract][Full Text] [Related]
6. Does health technology assessment compromise access to pharmaceuticals?
Büssgen M; Stargardt T
Eur J Health Econ; 2023 Sep; 24(7):1245-1248. PubMed ID: 37336862
[TBL] [Abstract][Full Text] [Related]
7. Understanding the first-offer conundrum: How buyer offers impact sale price and impasse risk in 26 million eBay negotiations.
Schweinsberg M; Petrowsky HM; Funk B; Loschelder DD
Proc Natl Acad Sci U S A; 2023 Aug; 120(32):e2218582120. PubMed ID: 37527338
[TBL] [Abstract][Full Text] [Related]
8. [The transparency committee of the French National Authority for Health].
Lengliné E
Bull Cancer; 2024 Feb; 111(2):228-234. PubMed ID: 38176970
[TBL] [Abstract][Full Text] [Related]
9. Provenance and Clinical Benefit of Medicines Introduced to the French Market, 2008 to 2018.
Osipenko L; Potey P; Perez B; Kupryjanczuk A; Angelov F; Schuster A; Mossialos E
JAMA Intern Med; 2024 Jan; 184(1):46-52. PubMed ID: 37983026
[TBL] [Abstract][Full Text] [Related]
10. The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany.
Dintsios CM; Beinhauer I
Health Econ Rev; 2020 Mar; 10(1):7. PubMed ID: 32172494
[TBL] [Abstract][Full Text] [Related]
11. Benefit assessment in Germany: implications for price discounts.
Theidel U; von der Schulenburg JM
Health Econ Rev; 2016 Dec; 6(1):33. PubMed ID: 27485438
[TBL] [Abstract][Full Text] [Related]
12. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
[TBL] [Abstract][Full Text] [Related]
13. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
14. [Benefit Assessment and Price Negotiation Under AMNOG: Calculable Process or Unfair Poker Game?].
Radic D; Haugk S; Radic M
Gesundheitswesen; 2018 Jun; 80(6):573-579. PubMed ID: 27636366
[TBL] [Abstract][Full Text] [Related]
15. The Impact Of Price Regulation On The Availability Of New Drugs In Germany.
Stern AD; Pietrulla F; Herr A; Kesselheim AS; Sarpatwari A
Health Aff (Millwood); 2019 Jul; 38(7):1182-1187. PubMed ID: 31260362
[TBL] [Abstract][Full Text] [Related]
16. Early benefit assessment of new drugs in Germany - results from 2011 to 2012.
Hörn H; Nink K; McGauran N; Wieseler B
Health Policy; 2014 Jun; 116(2-3):147-53. PubMed ID: 24472328
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
